Literature DB >> 22552531

Renin-angiotensin system inhibitors and angioedema: anesthetic implications.

Ljuba Stojiljkovic1.   

Abstract

PURPOSE OF REVIEW: Angioedema is a serious complication of renin-angiotensin system inhibitor therapy. The incidence is 0.1-0.7%. It consists of nonpitting edema and involves the face and lips. In severe cases, it extends to pharyngeal and laryngeal structures. RECENT
FINDINGS: Decreased degradation of bradykinin and its metabolites is thought to be a culprit. When the angiotensin-converting enzyme is inhibited, bradykinin metabolism is dependent on degradation by neutral endopeptidase, dipeptidyl peptidase IV, and aminopeptidase P. When these enzymes are inhibited, as in treatment of diabetes or in transplant recipients, the incidence of angioedema increases significantly. African-Americans, people over 65, women, and those with a history of smoking are especially at risk. A fiberoptic laryngeal examination should be performed in all patients. Patients with rapid progression of symptoms are at risk for airway compromise. Supportive treatment with steroids and antihistamines is not very effective. Recently, icatibant, a bradykinin receptor antagonist, has been used to successfully shorten the resolution of edema.
SUMMARY: Trauma of the airway, especially during difficult intubation, may precipitate severe angioedema. In cases with laryngeal involvement, fiberoptic intubation may be necessary. After the episode of angioedema, lifetime discontinuation of all renin-angiotensin inhibitors may be warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552531     DOI: 10.1097/ACO.0b013e328352dda5

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  6 in total

1.  Propensity score methods for confounding control in nonexperimental research.

Authors:  M Alan Brookhart; Richard Wyss; J Bradley Layton; Til Stürmer
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-09-10

2.  [Acute non-allergic angioedema. Rare cause for intensive care unit admission].

Authors:  V van der Heide; T Woehrle; M Ripperger; V Huge
Journal:  Anaesthesist       Date:  2015-07-21       Impact factor: 1.041

3.  A consensus parameter for the evaluation and management of angioedema in the emergency department.

Authors:  Joseph J Moellman; Jonathan A Bernstein; Christopher Lindsell; Aleena Banerji; Paula J Busse; Carlos A Camargo; Sean P Collins; Timothy J Craig; William R Lumry; Richard Nowak; Jesse M Pines; Ali S Raja; Marc Riedl; Michael J Ward; Bruce L Zuraw; Deborah Diercks; Brian Hiestand; Ronna L Campbell; Sandra Schneider; Richard Sinert
Journal:  Acad Emerg Med       Date:  2014-04       Impact factor: 3.451

4.  Postanesthetic Severe Oral Angioedema in Patient's Taking Angiotensin-Converting Enzyme Inhibitor.

Authors:  Acílio Marques; Carla Retroz-Marques; Sara Mota; Raquel Cabral; Matos Campos
Journal:  Case Rep Anesthesiol       Date:  2014-11-06

5.  Severe angioedema of laryngeal inlet in a woman receiving telmisartan therapy undergoing breast conservation surgery.

Authors:  Bikram Kishore Behera; Satyajeet Misra; Madhabananda Kar
Journal:  Indian J Anaesth       Date:  2018-05

Review 6.  Angioedema: Classification, management and emerging therapies for the perioperative physician.

Authors:  Lopa Misra; Narjeet Khurmi; Terrence L Trentman
Journal:  Indian J Anaesth       Date:  2016-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.